Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Appointed director
Sage Therapeutics, Inc. (SAGE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress"
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"
08/02/2022 8-K Quarterly results
Docs: "Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"
05/03/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress"
08/03/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress"
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sage Therapeutics Announces Third Quarter 2020 Financial Results and Highlights Pipeline and Business Progress"
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Securities registered pursuant to Section 12 of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, par value $0.0001 per share SAGE The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as ...",
"Sage Therapeutics Announces Second Quarter 2019 Financial Results and Highlights Pipeline and Business Progress"
05/02/2019 8-K Quarterly results
Docs: "Sage Therapeutics Announces First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress"
11/06/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Sage Therapeutics Announces Third Quarter 2018 Financial Results and Highlights Pipeline and Business Progress"
08/07/2018 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registra...",
"Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress"
05/03/2018 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934 . Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registra...",
"Sage Therapeutics Announces First Quarter 2018 Financial Results and Provides Update on Pipeline and Progress toward Launch Readiness"
08/03/2017 8-K Quarterly results
Docs: "Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update"
05/09/2017 8-K Form 8-K - Current report
02/23/2017 8-K Form 8-K - Current report
11/03/2016 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
02/24/2016 8-K Quarterly results
Docs: "Sage Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results"
11/05/2015 8-K Quarterly results
Docs: "SAGE Announces Third Quarter 2015 Financial Results and Recent Pipeline Progress"
08/12/2015 8-K Quarterly results
Docs: "SAGE Therapeutics Announces Second Quarter 2015 Financial Results and Highlights Recent Progress"
05/14/2015 8-K Quarterly results
Docs: "SAGE Therapeutics Announces SAGE-547 Progress and First Quarter 2015 Financial Results"
02/27/2015 8-K Quarterly results
Docs: "SAGE Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results"
11/12/2014 8-K Quarterly results
Docs: "SAGE Therapeutics Reports Third Quarter 2014 Results",
"SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients with Super-Refractory Status Epilepticus"
08/14/2014 8-K Quarterly results
Docs: "SAGE Therapeutics Reports Second Quarter 2014 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy